0N6A Stock Chart & Stats
€0.18
<€0.01(3.51%)
At close: 4:00 PM EDT
€0.18
<€0.01(3.51%)
Day’s Range― - ―
52-Week Range€0.03 - €0.18
Previous CloseN/A
Volume0.00
Average Volume (3M)3.35K
Market Cap
€11.77M
Enterprise Value€7.36M
Total Cash (Recent Filing)€2.02M
Total Debt (Recent Filing)€2.39M
Price to Earnings (P/E)―
Beta-0.16
Next Earnings
Apr 29, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding94,988,980
10 Day Avg. Volume0
30 Day Avg. Volume3,350
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-3.89
Price to Sales (P/S)0.00
P/FCF Ratio-1.80
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.15
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Focused Oncology Development PlatformA concentrated focus on cancer drug development, with particular attention to CNS malignancies, gives the company a defined strategic direction. Advancing candidates through preclinical, clinical, and translational work could support future commercialization or partnering if development milestones are achieved.
Losses Narrowed From Prior Peak LevelsThe reduction in losses from the 2021–2022 levels indicates some improvement in financial performance, even though the company remains unprofitable. If maintained, tighter loss control could extend available funding and improve the ability to prioritize development activities.
Historical Cash-burn ImprovementOperating and free cash-flow burn improved significantly from the highest levels shown in 2021–2022. Although cash generation remains negative and worsened again in 2025, the prior improvement demonstrates that spending intensity has not been uniformly deteriorating.
Bears Say
Pre-commercial Revenue BaseA near-zero or absent revenue base means the company currently lacks recurring commercial inflows to fund operations. This leaves financial progress dependent on successful clinical development and future commercialization or partnering rather than an established revenue engine.
Persistent Losses And Negative Cash FlowPersistent operating losses and negative free cash flow show that the business is not yet self-funding. Continued cash consumption can restrict development flexibility and requires the company to secure external funding while its therapeutic programs remain in development.
Negative Equity And Rising DebtNegative shareholders’ equity combined with sharply higher debt indicates elevated solvency and financing risk. The shrinking capital base and unstable leverage profile may limit financial flexibility, increase dependence on external capital, and constrain sustained investment in the pipeline.
TME Pharma N.V. News
0N6A FAQ
What was TME Pharma N.V.’s price range in the past 12 months?
TME Pharma N.V. lowest stock price was €0.03 and its highest was €0.18 in the past 12 months.
What is TME Pharma N.V.’s market cap?
TME Pharma N.V.’s market cap is €11.77M.
When is TME Pharma N.V.’s upcoming earnings report date?
TME Pharma N.V.’s upcoming earnings report date is Apr 29, 2027 which is in 180 days.
How were TME Pharma N.V.’s earnings last quarter?
TME Pharma N.V. released its earnings results on Oct 30, 2026. The company reported -€0.005 earnings per share for the quarter.
Is TME Pharma N.V. overvalued?
According to Wall Street analysts TME Pharma N.V.’s price is currently Overvalued.
Does TME Pharma N.V. pay dividends?
TME Pharma N.V. does not currently pay dividends.
What is TME Pharma N.V.’s EPS estimate?
TME Pharma N.V.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does TME Pharma N.V. have?
TME Pharma N.V. has 94,988,980 shares outstanding.
What happened to TME Pharma N.V.’s price movement after its last earnings report?
TME Pharma N.V. reported an EPS of -€0.005 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of TME Pharma N.V.?
Currently, no hedge funds are holding shares in DE:0N6A
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
TME Pharma N.V.
TME Pharma N.V., a biopharmaceutical company in the clinical development stage based in Berlin, Germany, is dedicated to pioneering innovative therapeutic solutions for cancer. The company leverages its unique Spiegelmer platform to advance a pipeline of investigational drug candidates. Its primary oncology asset, NOX-A12, is currently being evaluated in clinical studies as a combination therapy for a range of challenging cancers, including metastatic pancreatic and colorectal cancer, glioblastoma, and myeloma. Beyond its cancer-focused efforts, TME Pharma also developed NOX-E36, which has successfully concluded Phase 1/2 clinical trials for diabetic nephropathy. The company has formed a strategic collaboration with Merck Sharp & Dohme Corp. to explore NOX-A12 in combination with Keytruda and two different chemotherapy protocols as a second-line intervention for patients battling metastatic pancreatic cancer. Founded in 1997, the organization adopted its current name, TME Pharma N.V., in July 2022, having previously operated as NOXXON Pharma N.V.
Technical Analysis
Innate Pharma SA
―
Nanobiotix
―
Transgene
―
OSE Immunotherapeutics SA
―
Cellectis SA
―